Home/Pipeline/Vitiligo Candidate

Vitiligo Candidate

Vitiligo

Phase 2ActiveN/A

Key Facts

Indication

Vitiligo

Phase

Phase 2

Status

Active

Company

Teva

About Teva

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical leader with a dual strategy of being a generics/biosimilars powerhouse and an innovative specialty medicines developer. Its mission, 'We are all in for better health,' is executed through a focus on neuroscience and immunology, leveraging strategic partnerships and a robust pipeline. The company is currently in the 'Acceleration Phase' of its 'Pivot to Growth' plan, aiming for consistent financial performance and pipeline execution, having delivered three consecutive years of growth as of 2025.

View full company profile

Therapeutic Areas

Neuroscience Immunology

Other Vitiligo Drugs

Drug	Company	Phase	Status
PEP Biologic™	Intent Biologics	Unknown	Active
Adimune	Aditxt	Preclinical	Active
Therapeutic Vaccine	2A Pharma	Pre-clinical	Active
CGB-600	CAGE Bio	Phase 2	Active
Vitiligo Trial	Well Pharma Medical Research	Not Specified	Active
Novel Immunology Candidate	Teva Pharmaceutical Industries	Phase 2	Active
Opzelura (ruxolitinib cream)	Incyte	Marketed	Active
Topical Roflumilast Foam 0.3%	Arcutis Biotherapeutics	Phase 2	Proof-of-concept ongoing
SCENESSE® (afamelanotide)	Clinuvel Pharmaceuticals	Phase III	Active (CUV156)
EB06	Edesa Biotech	Phase 1	Active